Related Experiment Video
Updated: Mar 14, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Innovative in vitro methodologies for establishing therapeutic equivalence
Summary
Latin American countries can improve pharmaceutical quality by using biowaivers, which exempt certain generic drugs from clinical bioequivalence studies. Innovative in vitro tools can enhance regulatory strategies for faster patient access to quality medicines.
Area of Science:
- Pharmaceutical Sciences
- Regulatory Science
- Drug Development
Background:
- Latin American countries require bioequivalence for generic drugs, posing challenges due to the large number of products.
- Clinical bioequivalence studies are not feasible for all products, necessitating alternative strategies.
- The United States Food and Drug Administration (FDA) uses Biopharmaceutics Classification System (BCS)-based biowaivers to streamline drug development.
Purpose of the Study:
- To explore the potential of biowaivers and in vitro techniques to address regulatory challenges in Latin America.
- To accelerate patient access to quality generic pharmaceutical products.
- To enhance the reliability of in vitro dissolution data for predicting in vivo performance.
Main Methods:
- Review of biowaiver strategies based on the Biopharmaceutics Classification System (BCS).
- Assessment of in vitro dissolution and absorption systems (IDAS) for formulation development.
- Integration of in vitro dissolution and permeability tests.
Main Results:
- Biowaivers significantly reduce development time, cost, and unnecessary human exposure.
- In vitro dissolution and absorption systems (IDAS) can improve the translation of in vitro data to in vivo performance.
- Formalizing in vitro techniques can provide cost-effective solutions for regulatory challenges.
Conclusions:
- Biowaivers and advanced in vitro methods offer viable solutions for pharmaceutical quality and regulatory hurdles in Latin America.
- These strategies can expedite patient access to safe and effective generic medications.
- Regulatory science initiatives are crucial for the successful implementation of these innovative tools.
Related Concept Videos
01:17Equivalence: In Vitro and In Vivo Bioequivalence
309
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
309
01:13Bioequivalence studies: Biowaivers
367
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
367
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
204
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
204
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
235
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
235
01:17In Vitro Drug Dissolution: Alternative Methods
322
Alternative drug dissolution methods include the rotating bottle, intrinsic dissolution test, peristalsis, and the Franz diffusion cell method. The rotating bottle method involves meticulously rotating tightly capped controlled-release beads in a temperature-controlled bath. Periodic decanting of samples allows for residue assay, followed by refilling with fresh medium and testing at various pH levels to emulate the gastrointestinal tract conditions.In contrast, the intrinsic dissolution test...
322
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K